Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer
(2022) In International Journal of Gynecological Cancer 32(Suppl 2). p.405-405- Abstract
- Introduction/Background
Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.
Methodology
Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples,... (More) - Introduction/Background
Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.
Methodology
Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency.
Results
Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (p_trend (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/e9a918a5-9d0c-4989-b8de-2b1beed6cf47
- author
- Dobilas, Arturas LU ; Leandersson, Pia LU ; Chen, Yilun LU ; Alcaide, Miguel ; Brueffer, Christian LU ; Saal, Lao LU and Borgfeldt, Christer LU
- organization
- publishing date
- 2022-10-20
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Ovarian cancer, Gynecological cancer disease, Minimal residual disease, Liquid biopsy, ctDNA
- in
- International Journal of Gynecological Cancer
- volume
- 32
- issue
- Suppl 2
- article number
- 2022-RA-627-ESGO
- pages
- 405 - 405
- publisher
- BMJ Publishing Group
- ISSN
- 1048-891X
- DOI
- 10.1136/ijgc-2022-ESGO.868
- language
- English
- LU publication?
- yes
- id
- e9a918a5-9d0c-4989-b8de-2b1beed6cf47
- date added to LUP
- 2023-10-03 09:53:20
- date last changed
- 2023-10-04 02:30:50
@misc{e9a918a5-9d0c-4989-b8de-2b1beed6cf47, abstract = {{Introduction/Background<br/>Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinico-pathological parameters and patient outcome.<br/><br/>Methodology<br/>Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency.<br/><br/>Results<br/>Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (p_trend}}, author = {{Dobilas, Arturas and Leandersson, Pia and Chen, Yilun and Alcaide, Miguel and Brueffer, Christian and Saal, Lao and Borgfeldt, Christer}}, issn = {{1048-891X}}, keywords = {{Ovarian cancer; Gynecological cancer disease; Minimal residual disease; Liquid biopsy; ctDNA}}, language = {{eng}}, month = {{10}}, note = {{Conference Abstract}}, number = {{Suppl 2}}, pages = {{405--405}}, publisher = {{BMJ Publishing Group}}, series = {{International Journal of Gynecological Cancer}}, title = {{Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer}}, url = {{http://dx.doi.org/10.1136/ijgc-2022-ESGO.868}}, doi = {{10.1136/ijgc-2022-ESGO.868}}, volume = {{32}}, year = {{2022}}, }